Venture Kick

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

Nerai Bio is a biotechnology company that specializes in advancing genetic therapies. It operates an AI-assisted CRISPR protein engineering platform, enabling clients to enhance the development of next-generation therapeutic systems.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Abrinca Genomics is a biotechnology company specializing in the development of a web-based platform for managing and analyzing microbial genomics data. The platform is designed to be self-hosted, scalable, and dataset-independent, allowing researchers and bioinformaticians to securely organize, explore, and analyze vast volumes of microbial genome data. It supports multiple annotation formats, offers flexible access controls, and integrates seamlessly into existing workflows.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Aukera Therapeutics is a biotechnology company focused on developing innovative therapeutics targeting the mTOR protein pathway. Its primary focus lies in treating diseases such as cancer and neurodegenerative disorders.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Adaptyv Bio is a biotechnology company focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company's innovative technology aims to identify new antibodies for the treatment of various diseases by bridging the gap between computational predictions and experimental validation. Through its advanced methodologies, Adaptyv Bio seeks to enhance the efficacy of therapeutic interventions, ultimately improving patient outcomes.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company developing a microfluidic discovery platform for drug screening that targets membrane receptors, notably G-protein coupled receptors. The platform blends a lab-on-chip system with biological assays to quantify GPCR activation in primary mammalian cells, including guanosine 5'-O-(3-thiotriphosphate)-based functional readouts, and supports both ready-to-use and custom stable cell lines. This approach enables pharmaceutical researchers to investigate receptor signaling, identify drug modes of action, and perform in-vitro screenings directly on patient-derived cells. By enabling faster, more predictive screenings, ArcoScreen aims to reduce clinical attrition and accelerate the development of therapeutic candidates with improved translational relevance.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Bionomous develops innovative devices that automatically inspect and sort miniature biological entities using advanced micro-engineering design and machine learning methods. These devices facilitate studies in genetics, development, behavioral biology, toxicology, and other biotech applications.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

LifeMatrix is a biotechnology company focused on the development of biomimetic implants and bio-engineering technologies aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company specializes in human cell-derived, off-the-shelf tissue-engineered implants that integrate with the patient's body post-implantation, allowing them to grow and regenerate. This innovative approach addresses the limitations of traditional implants, promoting faster recovery and improved outcomes for patients. LifeMatrix's technology is supported by over 20 years of research, resulting in more than 100 peer-reviewed publications and extensive preclinical studies demonstrating safety and efficacy, paving the way for clinical applications. The company's advancements are bolstered by various national and international research grants, reflecting its commitment to transforming the field of regenerative medicine.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Bionomous develops innovative devices that automatically inspect and sort miniature biological entities using advanced micro-engineering design and machine learning methods. These devices facilitate studies in genetics, development, behavioral biology, toxicology, and other biotech applications.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Prolongate is a protein drugs and biotech company.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

Viventis Microscopy develops an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples, such as embryos and organoids. The company provides both the hardware and custom microscope control software, facilitating advanced imaging capabilities for researchers and organizations. By enabling detailed observation of delicate biological structures, Viventis Microscopy supports efforts in drug development and other scientific endeavors, helping to accelerate research and enhance the understanding of complex biological processes.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Lipidon is a bioanalytical service company that specializes in lipid research and lipidomics analytical services. The company focuses on identifying and developing novel biomarkers tailored for the life sciences, cosmetic, and food industries. By providing actionable biomarker discovery, Lipidon aids in precision medicine and various sectors, including pharmaceuticals, biotechnology, cosmetics, and food. The company’s services enable clients to distinguish between products of animal and herbal origin, facilitating informed decision-making in their respective fields.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

UniteLabs is an automation infrastructure platform for life-science lab automation. It connects hardware and software across vendor boundaries to digitalize research and development, enabling rapid design and deployment of custom workflows. The platform provides bidirectional connectors for diverse lab equipment, a scalable cloud platform with an open API, and a powerful workflow engine with an integrated compute environment, enabling real-time control and modular workflows. It supports Lab-as-Code with a dynamic Python SDK and application-specific components, and combines digital lab infrastructure with open-source tools, a growing connector library, and SDKs for API access. The platform is designed for ambitious biotech companies, large pharmaceutical organizations, integrators, and hardware vendors to automate and optimize experimental processes, improving quality, reproducibility, and throughput. UniteLabs is based in Basel, Switzerland.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Gnubiotics Sciences SA is a biotechnology company based in Epalinges, Switzerland, focused on developing microbiome-modulating products for both humans and animals. Founded in 2016, the company specializes in producing glycans that enhance microbiome diversity and promote gut health. One of its notable products, AMObiomeTM, serves as a natural ingredient aimed at improving microbiome balance and overall wellness. Gnubiotics is also engaged in creating functional and structural mimics of Human Milk Oligosaccharides, which are designed to replicate the beneficial properties of breast milk. These innovations are intended to prevent infections, combat diet-induced obesity, and support immune health by nurturing a diverse microbiome.

Certus Molecular Diagnostics AG specializes in the development and provision of molecular rapid tests designed for the on-site detection of mycoplasma contamination in cell cultures, as well as the identification of specific genes in various microorganisms. Founded in 2007 and headquartered in Bern, Switzerland, the company aims to enhance the reliability and efficiency of microbial testing in laboratory settings. By focusing on rapid diagnostics, Certus Molecular Diagnostics addresses critical needs in research and clinical environments, offering solutions that facilitate timely decision-making and quality control in cell culture processes. The company serves both domestic and international markets, contributing to advancements in molecular diagnostics.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

Gnubiotics Sciences SA is a biotechnology company based in Epalinges, Switzerland, focused on developing microbiome-modulating products for both humans and animals. Founded in 2016, the company specializes in producing glycans that enhance microbiome diversity and promote gut health. One of its notable products, AMObiomeTM, serves as a natural ingredient aimed at improving microbiome balance and overall wellness. Gnubiotics is also engaged in creating functional and structural mimics of Human Milk Oligosaccharides, which are designed to replicate the beneficial properties of breast milk. These innovations are intended to prevent infections, combat diet-induced obesity, and support immune health by nurturing a diverse microbiome.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

Cellphmed is a biotechnology company focused on advancing genomic research through its innovative tools that explore uncharted regions of the genome. The company specializes in developing human cell barcodes that utilize next-generation RNA sequencing technology, allowing for the verification of human cell identity and quality. By deciphering millions of previously unexplored RNA biomarkers, Cellphmed enables biomedical researchers to access vast amounts of genomic information. This capability supports critical areas such as virology, oncology, drug discovery, and diagnostics, facilitating enhanced human cell qualification and the development of new therapeutic strategies.

Embion Technologies SA, founded in 2016 and based in Ecublens, Switzerland, specializes in the extraction of prebiotic ingredients from industrial plant byproduct feedstocks for both human and animal nutrition. The company focuses on developing and marketing advanced bioactive nutritional ingredients that support sugar reduction and microbiome health. By employing innovative biomass processing technology, Embion aims to produce natural, sustainable products with low emissions and high functionality, addressing the growing global demand for nutrition and promoting a circular bioeconomy. Their unique approach not only enhances the efficiency of product development but also significantly reduces costs and time-to-market for clients in the nutrition sector.

Founded in 2016 and based in Zurich, Switzerland, Synple Chem specializes in the manufacture of automated reagent cartridge-based synthesizers. Its products, such as Synple 1 and Synple 2, accelerate drug research by enabling rapid synthesis of molecules, improving efficiency, and reducing reaction times.

Haelixa LLC, founded in 2012 and based in Zürich, Switzerland, specializes in DNA-based tracing and tagging technology aimed at enhancing supply chain transparency and integrity. The company develops innovative tracing solutions for various sectors, including the energy industry, where it offers water and oil tracers to monitor the movement of fluids in subsurface environments, as well as groundwater tracing solutions. Beyond the energy sector, Haelixa provides product identification solutions that help prevent counterfeiting and other irregularities, thereby reinforcing supply chain sustainability. Its proprietary platform enables clients to physically mark, trace, and authenticate products from production to retail, ensuring brand protection and proof of authenticity for a wide range of goods, including textiles and precious materials.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Selmod, based in Basel's life science hub, develops innovative antibiotics targeting multi-drug resistant infections. Its first-in-class drug candidates focus on high-revenue hospital patients where first-line treatments have failed due to resistance. With a disruptive approach featuring new dual modes of action, all candidates have shown success in animal infection studies. The company aims to capture a significant share of the estimated $9 billion total available market for its three lead assets.

ImmuProbe develops a protein quantification system, which is characterized by both an outstanding performance at very small sample volumes as well as low acquisition and consumable costs. We designed an approach to outmatching state-of-the-art technology in terms of usability, speed, and customisability: the BoxProbe. With this system, we intend to overcome the current limitations in research studies relying on small laboratory animals, resulting in improved quality of obtained data and drastically decreasing the number of animals needed, allowing scientists to efficiently apply the principles of the three Rs (replace, refine, reduce) of animal welfare. In the long-term future, we will apply our technology to improve the present practice in infant diagnostics.

SiMPLInext SA is a biotechnology company founded in 2016 and headquartered in Biel/Bienne, Switzerland. The company specializes in the development of cell-based assays, protocols, and in-vitro substances that enhance biological research. Its technologies enable biologists to investigate the permeability of biological membranes to nanoparticles, and also extend permeability studies to non-cellular membranes like mucuses and biofilms. By facilitating the observation of cellular cross-transport, SiMPLInext aims to advance in-vitro research through innovative and ergonomic solutions.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

TwentyGreen is a Swiss company that specializes in the production of probiotic feed supplements aimed at enhancing sustainable animal farming practices. Founded in 2015 and based in Root, Switzerland, the company has developed a unique triple active probiotic product that addresses challenges faced in intensive animal farming, such as improving digestion, enhancing feed conversion ratios, and reducing disease and pollution. The probiotic supplement is grounded in research from the École Polytechnique Fédérale de Lausanne, focusing on the enhancement of gut microbiota, which is crucial for food metabolism and immune defense. Targeting animal farmers, feed suppliers, and large retailers, TwentyGreen aims to capture a 10% share of the rapidly growing global animal feed probiotic market, which exceeds $4 billion annually. The commercialization of their product involves rigorous research and development in collaboration with esteemed academic partners to meet regulatory standards for animal feed.

NeuroCycle Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of small molecule drugs that target the nervous system. The company's primary focus is on sub-type selective GABA-A modulation, aiming to deliver next-generation treatments for chronic itch, pain, and certain refractory forms of pediatric epilepsy. Their lead candidate, NCT10004, has demonstrated significant efficacy across various models without causing sedation, immune suppression, dependency/addiction issues, or losing effectiveness over time.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

SiMPLInext SA is a biotechnology company founded in 2016 and headquartered in Biel/Bienne, Switzerland. The company specializes in the development of cell-based assays, protocols, and in-vitro substances that enhance biological research. Its technologies enable biologists to investigate the permeability of biological membranes to nanoparticles, and also extend permeability studies to non-cellular membranes like mucuses and biofilms. By facilitating the observation of cellular cross-transport, SiMPLInext aims to advance in-vitro research through innovative and ergonomic solutions.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Spectroswiss Sarl is a Swiss company established in 2014 and based in Lausanne, specializing in biological mass spectrometry. It develops advanced mass analyzers and data acquisition electronics designed to enhance research in life sciences and biotechnology. The company employs proprietary methods for processing time-domain data, enabling super-resolution signal processing in Fourier transform mass spectrometry (FTMS). This innovative approach allows clients to conduct both qualitative and quantitative analyses of proteins and metabolites, facilitating vital research and applications in the life sciences sector. Spectroswiss aims to accelerate scientific discovery by providing sophisticated tools for proteomics and metabolomics analysis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

AlveoliX is a Swiss biotechnology company based in Bern that develops organ-on-chip based in vitro lung models to support preclinical decision-making in drug development. Its lung-on-chip platforms reproduce key biophysical features of the lung to better predict human drug responses, with the goal of improving safety, reducing costs, and decreasing reliance on animal testing.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Ectica Technologies AG is a Zurich-based company that specializes in the development and manufacturing of hydrogel-based tools tailored for the biopharmaceutical and life sciences sectors. Founded in 2015, the company focuses on advancing 3D cell culture technologies to enhance drug discovery and bioresearch. Its flagship product, the 3D ProSeed Hydrogel well-plate, allows for high biological relevance in cell culture, closely mimicking the natural conditions found in the human body. This innovative technology facilitates automation-compatible cell-based assays, supporting pharmaceutical companies, contract research organizations, and academic laboratories in their preclinical drug discovery efforts. Additionally, Ectica Technologies offers services in assay development, technology integration, and custom production, catering especially to startup companies within the industry.

AlveoliX is a Swiss biotechnology company based in Bern that develops organ-on-chip based in vitro lung models to support preclinical decision-making in drug development. Its lung-on-chip platforms reproduce key biophysical features of the lung to better predict human drug responses, with the goal of improving safety, reducing costs, and decreasing reliance on animal testing.

Nanolive SA is a Swiss company that specializes in the design and development of advanced imaging devices for live cells. Established in 2013 and headquartered in Ecublens, Switzerland, the company offers the 3D Cell Explorer, a cutting-edge technology that allows researchers to visualize the interior of living cells in three dimensions without the need for labeling or invasive techniques. This innovative device enables detailed observation of various cellular processes such as cell division, organelle structure, cell morphology, differentiation, and interactions between cells. By capturing unbiased live cell data, Nanolive's technology supports the research and development of new drugs and therapies, facilitating quality analysis and providing valuable biological insights for scientists and researchers in the field of life sciences.